Vertex Pharmaceuticals Incorporated (VRTX)
After hours:
| Previous close | 467.97 |
| Open | 467.49 |
| Bid | 473.60 x 700 |
| Ask | 474.40 x 100 |
| Day's range | 464.85 - 477.00 |
| 52-week range | 341.90 - 510.64 |
| Volume | |
| Avg. volume | 1,092,698 |
| Market cap | 122.895B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
BOSTON, October 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Third Quarter 2024 Earnings Call."
- Business Wire
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
BOSTON, September 26, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor ("vanza triple") — the potential next-in-class triple combination medicine — will take place at the North American Cystic Fibrosis Conference (NACFC). Vertex also announced presentations describing long-term outcomes in people with cystic fibrosis (CF) ages 2 to 11 years t
- Business Wire
Vertex to Participate in Upcoming September Investor Conferences
BOSTON, August 22, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
